Veronica Guerra

Dr. Veronica Guerra

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
CDCourtney Dinardo
Courtney Dinardo
DVDivij Verma
Divij Verma
Natalia BaranNatalia Baran
Natalia Baran
TBTushar D. Bhagat
Tushar D. Bhagat
ASAnna Skwarska
Anna Skwarska
MKMarina Konopleva
Marina Konopleva

31 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CRCarla Cristina Romagnoli
Carla Cristina Romagnoli
VGVeronica Guerra
Veronica Guerra
LSLeily Santos
Leily Santos
MOMarisol Ocampo
Marisol Ocampo
ALAlexandra Lyubimova
Alexandra Lyubimova
Jacqueline C. BarrientosJacqueline C. Barrientos
Jacqueline C. Barrientos
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) and high-grade follicular lymphoma (FL) are aggressive B-cell malignancies predominantly affecting older adults. R-CHOP remains the frontline standard of care, with frail and elderly patients requiring attenuated regimens such as R-mini-CHOP. Real-world comparative data in elderly and Hispanic populations remain limited. We aimed to evaluate outcomes of R-mini-CHOP versus R-CHOP in elderly patients and to explore potential differences by ethnicity. Methods: Single-center retrospective analysis of adult patients older than 70 years with DLBCL and high-grade FL, treated between January 2014 and June 2025. Clinical characteristics, treatment responses, and survival outcomes were analyzed. The overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method. Results: A total of 136 patients were included (72 R-mini-CHOP; 64 R-CHOP). Patients receiving R-mini-CHOP were older (median 82 vs. 74 years) and had higher-risk features. Overall response rates were 88.7% and 92.6% in the R-mini-CHOP and R-CHOP groups, respectively. Two-year OS was 79.3% for R-mini-CHOP and 76.7% for R-CHOP. Median OS and PFS were not reached in either group. Elevated lactate dehydrogenase (LDH) was associated with an inferior response. We identified a trend toward better response with R-CHOP in Hispanic patients, although this was not statistically significant. Conclusions: In this real-world cohort, R-mini-CHOP achieved response and survival outcomes comparable to R-CHOP despite worse baseline characteristics. These findings support the use of dose-attenuated therapy in frail and elderly patients and suggest that equitable access to care may mitigate ethnic disparities in outcomes.